The purpose of this study is to understand how fosmanogepix is processed in people with varying degrees of liver dysfunction.
This study is seeking participants who have:
stable loss of liver function with mild, moderate, or advanced severity
none of underlying conditions possibly affecting the study medicine being absorbed by the body
liver dysfunction not due to acute worsening of liver
All participants will receive 1 dose of fosmanogepix by mouth before breakfast on the first day at the study clinic. Serial blood samples will be collected to understand how fosmanogepix is changed and eliminated from the body. Participants will also receive physical examination and other tests. This will help to understand if fosmanogepix is safe.
Participants will be involved in this study for 4 to 9 weeks (maximum). There will be 2 to 4 study visits at the study clinic.